Torrent Pharmaceuticals Ltd. came under fire in an 8 October US Food and Drug Administration warning letter for failing to properly validate the use of an alternate active pharmaceutical ingredient in its manufacturing process for losartan potassium tablets.
The warning letter resulted from the agency’s ongoing global investigation into potentially carcinogenic nitrosamine impurities in valsartan and other angiotensin II receptor blockers, including losartan.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?